Australia markets closed
  • ALL ORDS

    7,709.50
    +21.50 (+0.28%)
     
  • ASX 200

    7,493.80
    +25.50 (+0.34%)
     
  • AUD/USD

    0.7117
    -0.0001 (-0.01%)
     
  • OIL

    82.02
    +1.01 (+1.25%)
     
  • GOLD

    1,926.40
    -3.60 (-0.19%)
     
  • BTC-AUD

    32,292.49
    -283.29 (-0.87%)
     
  • CMC Crypto 200

    520.79
    -6.40 (-1.21%)
     
  • AUD/EUR

    0.6534
    +0.0005 (+0.08%)
     
  • AUD/NZD

    1.0951
    -0.0009 (-0.09%)
     
  • NZX 50

    12,036.05
    +12.59 (+0.10%)
     
  • NASDAQ

    12,051.48
    +236.79 (+2.00%)
     
  • FTSE

    7,766.79
    +5.68 (+0.07%)
     
  • Dow Jones

    33,949.41
    +205.57 (+0.61%)
     
  • DAX

    15,151.91
    +19.06 (+0.13%)
     
  • Hang Seng

    22,688.90
    +122.12 (+0.54%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     

Evoke Pharma Third Quarter 2022 Earnings: Beats Expectations

Evoke Pharma (NASDAQ:EVOK) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$832.1k (down 11% from 3Q 2021).

  • Net loss: US$2.01m (loss widened by 2.3% from 3Q 2021).

  • US$0.60 loss per share.

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Evoke Pharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 45%. Earnings per share (EPS) also surpassed analyst estimates by 9.1%.

Looking ahead, revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 19% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Evoke Pharma (1 is a bit concerning!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here